Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $72 | $67 | $122 | $67 |
| Short-Term Investments | $0 | $5 | $0 | $35 |
| Receivables | $40 | $39 | $31 | $17 |
| Inventory | $48 | $39 | $25 | $18 |
| Other Curr. Assets | $7 | $6 | $9 | $5 |
| Total Curr. Assets | $168 | $156 | $187 | $143 |
| Property Plant & Equip (Net) | $28 | $29 | $10 | $7 |
| Goodwill | $23 | $23 | $23 | $23 |
| Intangibles | $99 | $110 | $121 | $131 |
| Long-Term Investments | $4 | $0 | $0 | $0 |
| Tax Assets | $6 | $0 | $0 | $0 |
| Other NC Assets | -$5 | $5 | $5 | $1 |
| Total NC Assets | $155 | $166 | $158 | $162 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $323 | $323 | $345 | $304 |
| Liabilities | – | – | – | – |
| Payables | $2 | $12 | $5 | $9 |
| Short-Term Debt | $21 | $3 | $2 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $77 | $80 | $67 | $70 |
| Total Curr. Liab. | $100 | $95 | $74 | $79 |
| LT Debt | $250 | $226 | $196 | $88 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $2 | $4 | $5 |
| Other NC Liab. | $2 | $6 | $26 | $37 |
| Total NC Liab. | $252 | $234 | $226 | $130 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $39 | $38 | $11 | $0 |
| Total Liabilities | $353 | $329 | $299 | $209 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$672 | -$617 | -$555 | -$460 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $642 | $610 | $600 | $555 |
| Total Equity | -$30 | -$7 | $45 | $95 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $323 | $323 | $345 | $304 |
| Net Debt | $200 | $162 | $76 | $21 |